AAVantgarde closed a $141 million Series B led by Amgen Ventures to advance gene therapies for inherited retinal diseases that cause blindness. The Milan‑based company said the financing will fund development of its pipeline programs targeting two retinal disorders and accelerate clinical translation. The round draws strategic interest from an established biopharma investor and signals continued venture capital appetite for AAV‑based ophthalmic programs. AAVantgarde plans to use proceeds for IND‑enabling studies and to scale manufacturing and development capabilities. The financing highlights the ongoing investor focus on rare ocular indications that have a defined regulatory pathway and precedents for successful gene‑therapy approvals.